Ss-31

Mechanism of action

SS-31 localizes to the inner mitochondrial membrane and binds to cardiolipin, a key phospholipid for the assembly and stability of respiratory complexes and supercomplexes. This interaction may: (1) improve the efficiency of electron transfer and reduce electron “leakage” that generates ROS; (2) limit cardiolipin peroxidation and cristae disorganization; (3) preserve membrane potential and ATP production; (4) attenuate pro-apoptotic signals linked to mitochondrial damage. The effect is often described as “mitochondrial protective” rather than as a simple free-radical scavenger.

Supported benefits

• Improvement in biomarkers and functional measures related to mitochondrial bioenergetics in preclinical models of mitochondrial damage (ischemia-reperfusion, aging, mitochondrial toxicity) (strong)
• Signals of improvement in muscle function/fatigability in some clinical or older populations (outcomes vary across studies, endpoints, and doses) (moderate)
• Possible support for cardiac or renal parameters in specific pathological conditions (heterogeneous results; not generalizable to healthy individuals) (moderate)
• Improvement in athletic performance in healthy athletes (VO2max, time trial, power): direct evidence limited/insufficient (limited)

Safety & side effects

• Injection-site reactions (pain, erythema, itching, induration): among the most commonly reported events
• Headache and gastrointestinal disturbances (e.g., nausea) reported in some studies
• Possible dizziness or nonspecific feelings of malaise (variable)
• General risks of parenteral administration: local infection, abscesses, allergic reactions, dosing errors

FAQ

Is SS-31 an antioxidant like vitamin C or E?

Not exactly. It is a mitochondria-targeted peptide that interacts with cardiolipin and may reduce ROS production by improving the efficiency of the respiratory chain. It is a more specific “mitochondrial protective” approach than generic antioxidants.

Can it increase VO2max or performance in healthy athletes?

Direct evidence in healthy athletes and performance endpoints (VO2max, time trial, power) is limited. Much of the data comes from preclinical models or populations with mitochondrial dysfunction, so it cannot be automatically extrapolated to competitive sport.

Why is it not considered a supplement?

Because it is a synthetic peptide developed as an experimental drug, administered parenterally in studies and subject to clinical/regulatory evaluation. It does not fall within the typical categories of oral supplementation.

What is the main practical risk outside a clinical trial?

In addition to adverse effects, the greatest risks are product quality/sterility, contamination, inaccurate dosing, and injection-related complications. Moreover, without clinical monitoring it is difficult to manage adverse events or interactions.

Does it act on mitochondrial biogenesis like training does?

Training (especially endurance and interval training) activates signaling pathways (e.g., PGC-1α) that increase biogenesis and oxidative capacity. SS-31 is primarily studied for stabilizing mitochondrial function and reducing damage/inefficiency; these are complementary but not equivalent mechanisms.